Diversify Wealth Management LLC Has $3.84 Million Stake in Edwards Lifesciences Corporation $EW

Diversify Wealth Management LLC reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 13.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,252 shares of the medical research company’s stock after selling 7,258 shares during the quarter. Diversify Wealth Management LLC’s holdings in Edwards Lifesciences were worth $3,842,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Edwards Lifesciences by 7.0% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after buying an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after acquiring an additional 10,078 shares in the last quarter. Arkadios Wealth Advisors acquired a new position in Edwards Lifesciences in the second quarter valued at about $300,000. Atlantic Union Bankshares Corp increased its holdings in shares of Edwards Lifesciences by 2,240.9% in the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after acquiring an additional 11,384 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp raised its position in shares of Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a report on Monday, November 3rd. The Goldman Sachs Group restated a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. BTIG Research reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Finally, Evercore reiterated an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $86.47 on Friday. The company has a fifty day moving average price of $82.74 and a two-hundred day moving average price of $81.22. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The stock has a market cap of $50.22 billion, a P/E ratio of 47.25, a P/E/G ratio of 2.24 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the business posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 67,804 shares of company stock worth $5,711,242. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.